Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 10, 2009

NCI to Undertake IND-Enabling Studies for Azaya’s Anticancer Agent

  • The NCI selected Azaya Therapeutics’ lead cancer therapy, ATI-1123, for further investigation. The institute will conduct ADMET studies to help the company file an IND.

    ATI-1123 is an advanced liposomal formulation of Taxotere. NCI’s Nanotechnology Characterization Laboratory (NCL) will conduct and fund the in vitro and in vivo studies on this molecule.

    The agreement is part of the NCI’s Alliance for Nanotechnology in Cancer. The NCL reports that it has developed a series of protocols that produce a characterization profile for many different kinds of nanoparticles with potential medical applications. These profiles include information on size, morphology, purity, chemical composition, and stability.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »